The needle is no longer the only way in.
As of November 2026, two GLP-1 pills are FDA-approved for weight loss: the Wegovy pill (oral semaglutide 25 mg, approved December 22, 2025) and Foundayo (orforglipron, approved April 1, 2026). Both start at $149 a month self-pay. A third oral GLP-1, semaglutide sold as Rybelsus and now also as Ozempic tablets, is approved for type 2 diabetes only. The Wegovy pill has a morning fasting rule; Foundayo can be taken any time, with or without food (Novo Nordisk; Eli Lilly).
🔑 Key Takeaways
- Two oral GLP-1s are now FDA-approved for weight loss: the Wegovy pill (oral semaglutide 25 mg, Novo Nordisk, December 22, 2025) and Foundayo (orforglipron, Eli Lilly, April 1, 2026).
- Efficacy is closer to injections than expected: the Wegovy pill averaged 13.6% weight loss counting everyone, and 16.6% for people who stayed on it, at 64 weeks.
- Orforglipron is easier to take: no fasting required, no water restriction — a genuine quality-of-life upgrade over oral semaglutide.
- Rybelsus and Ozempic tablets are NOT weight-loss drugs: they are oral semaglutide for type 2 diabetes at lower doses; some doctors prescribe them off-label.
- GI side effects are real but often milder than with injections, because absorption is slower and more gradual.
- More oral options are coming: Pfizer dropped danuglipron in April 2025, but aleniglipron and an oral form of zenagamtide (amycretin) are still in trials.
You already know injections work. What most people don't know is how close pills have gotten — and which one fits their life. The oral GLP-1 category went from a curiosity to a real clinical option almost overnight. Here's what's actually available, how it compares, and whether you're a candidate.
Which GLP-1 Pills Are FDA-Approved?
Three pills. Different indications, different mechanisms.
oral semaglutide, Novo Nordisk
orforglipron, Eli Lilly
oral semaglutide, Novo Nordisk
oral semaglutide, Novo Nordisk
orforglipron, Eli Lilly
oral semaglutide, Novo Nordisk
Prices are cash (self-pay) prices checked November 5, 2026 on wegovy.com, LillyDirect and the NovoCare Ozempic price guide. Foundayo's 2.5 mg and 5.5 mg prices are a temporary reduction through December 31, 2026, and the 14.5 mg and 17.2 mg price applies when you refill within 45 days. Doses and fasting rules are from the Wegovy, Foundayo and Rybelsus/Ozempic tablets prescribing information. Rybelsus and Ozempic tablets are not interchangeable mg for mg.
The headline story here is Foundayo. It's the first non-peptide oral GLP-1 receptor agonist to reach approval — meaning it's a small molecule drug, not a protein. That distinction matters more than it sounds, and we'll get to why in the next section.
How GLP-1 Pills Work
Oral delivery is hard. Proteins like semaglutide are destroyed in the stomach before they can be absorbed. That's why injections dominated for so long — they bypass digestion entirely.
Novo Nordisk solved this with SNAC technology (sodium N-(8-[2-hydroxybenzoyl] amino) caprylate). SNAC creates a temporary pH shift in the stomach lining that allows semaglutide to be absorbed directly through the stomach wall, not through the gut. The trade-off: you must take it in a fasted state, with no more than 4 ounces of water, and wait at least 30 minutes before eating or drinking anything else. Miss any part of this protocol — even a sip of coffee — and absorption drops significantly.
By week two or three, most people have the routine down. But for anyone with an irregular morning schedule, frequent travel, or a habit of eating right when they wake up, this protocol becomes the friction point that erodes compliance over time.
Orforglipron works differently at the molecular level. It's a small molecule — not a peptide — so it survives stomach acid on its own, absorbs through standard gut pathways, and doesn't require any fasting window. You can take it with food, with coffee, at any time of day. When you're dealing with a chronic treatment that lasts years, that flexibility isn't a minor perk — it's a major compliance driver.
GLP-1 Pills vs. Injections: The Real Difference
The gap is narrower than anyone expected.
Head-to-head snapshot (best available data):
- Injectable Wegovy (2.4mg/week): ~15% average body weight loss at 68 weeks (STEP 1 trial)
- Wegovy pill (semaglutide 25 mg daily): 13.6% average weight loss counting everyone, 16.6% for those who stayed on treatment, at 64 weeks (OASIS 4, Novo Nordisk)
- Foundayo (orforglipron, 17.2 mg daily): 11.1% counting everyone at 72 weeks, per the label; 12.4% for those who stayed on treatment (ATTAIN-1, NEJM 2025)
- Injectable Wegovy HD (7.2mg/week): 18.8% counting everyone, 20.7% for those who stayed on treatment, at 72 weeks (STEP UP, Novo Nordisk, March 19, 2026)
- Injectable tirzepatide (Mounjaro/Zepbound, 15mg): up to ~22.5% — still the efficacy ceiling for approved drugs
The honest verdict: the Wegovy pill lands within a couple of points of the 2.4mg Wegovy injection, and Foundayo a few points below both. The ceiling shifts with injectable dual agonists like tirzepatide, but for people choosing between an oral and a subcutaneous version of the same drug, the pill is no longer the consolation prize.
Where injections still have an edge: maximum achievable weight loss. At the highest doses of tirzepatide or high-dose semaglutide injection, the peak is higher. But the average patient isn't on max dose — and for the typical prescribed regimen, pills are now competitive enough that the format choice becomes a lifestyle decision, not a medical compromise.
Who Should Consider Oral GLP-1?
Not everyone. But more people than you'd think.
The strongest candidates for oral GLP-1:
- Needle-averse patients — an obvious fit, but worth naming directly. For people who have genuinely delayed starting treatment because of injection anxiety, a pill removes that barrier entirely.
- Frequent travelers — injectable GLP-1s require refrigeration, sharps disposal, and TSA considerations. Pills require none of this.
- People who struggled with injection compliance — if weekly glp 1 shots felt manageable in theory but kept slipping in practice, daily oral dosing may actually create more consistent habit anchoring.
- Rybelsus users with type 2 diabetes who want a weight-loss dose — you already know the morning routine, and the Wegovy pill (up to 25mg) uses the same one. Doses are not swapped mg for mg between these products, so your prescriber sets the new schedule.
- Anyone who tried orals before and found the fasting protocol too strict — orforglipron changes that calculation completely.
Who probably shouldn't switch: patients already achieving strong results on injectables, or people targeting maximum weight loss who want every percentage point of efficacy the category can offer. In those cases, injectable tirzepatide or high-dose semaglutide still leads.
What About Rybelsus?
Rybelsus is semaglutide — but it's not a weight-loss drug. Not officially.
FDA approved Rybelsus for type 2 diabetes management in 2019. The doses (3mg, 7mg, 14mg) were calibrated for glycemic control, not for weight loss. The current label (revised January 2026) also covers Ozempic tablets (1.5mg, 4mg, 9mg), a smaller oral semaglutide tablet for the same type 2 diabetes uses, and states that Rybelsus and Ozempic tablets are not substitutable on a mg-to-mg basis (prescribing information). The weight-loss version of oral semaglutide is the Wegovy pill, which steps up to 25mg.
Some physicians do prescribe Rybelsus off-label for weight management. If you're in that situation and weight loss is the primary goal, it's worth asking your doctor directly whether moving to the Wegovy pill is appropriate — assuming you meet the indication (BMI ≥30, or ≥27 with a weight-related condition).
Cost and Access
Prices are now public. Here's what they are as of November 2026.
The Wegovy pill costs $149 a month for the 1.5mg starting dose, $199 for 4mg and $299 for the 9mg and 25mg doses at self-pay, against a list price of $1,349.02 a package. With commercial insurance that covers it, the savings card can bring it down to as little as $25 a month (Novo Nordisk savings terms). Insurance coverage varies widely; many plans cover injectable GLP-1s for obesity under certain criteria, and the oral version may qualify under the same approvals, but verification with your insurer is essential before assuming coverage.
Foundayo (orforglipron) is sold self-pay through LillyDirect at $149 a month for 0.8mg and 2.5mg, $199 for 5.5mg and $299 for 9mg, 14.5mg and 17.2mg. The 2.5mg and 5.5mg prices are temporarily reduced through December 31, 2026, and the two top doses hold at $299 only when you refill within 45 days. Commercially insured patients with coverage may pay as little as $25 (LillyDirect, checked November 5, 2026).
On Medicare? The Medicare GLP-1 Bridge gives eligible Part D members a $50 monthly copay for certain GLP-1 drugs from July 1, 2026 through December 31, 2027, with prior authorization (CMS). Novo Nordisk says it covers every dose of the Wegovy pill, and Lilly lists Foundayo in the program.
Telehealth platforms — Hers, Calibrate, Found, WeightWatchers Clinic — are typically the fastest path to access for either drug. Most offer structured onboarding with a prescriber visit included in the monthly fee.
Side Effects
The GI profile is familiar — and often milder than you expect.
Oral GLP-1s carry the same class of side effects as injectables: nausea, vomiting, diarrhea, constipation, and stomach discomfort, particularly in the early weeks as dose titration begins. Most people notice these most at the start and during dose increases, not throughout the entire treatment.
The meaningful difference: because oral absorption is slower and produces a more gradual plasma concentration curve than a subcutaneous injection, the peak GLP-1 exposure at any given moment is lower. That translates to somewhat milder nausea for many patients — not zero, but not the same spike that some people experience in the hours following an injection.
One important caveat for oral semaglutide: if you don't follow the fasting protocol correctly, absorption drops dramatically — meaning you may be taking a pill that isn't working as intended. This matters for side effect management too. If absorption is erratic, so is the drug's effect, which can make titration harder to navigate.
If you're taking Foundayo (orforglipron), this concern doesn't apply. Absorption is consistent regardless of food timing.
What's Coming
The oral GLP-1 pipeline is full.
One name has dropped out. Pfizer stopped developing danuglipron in all indications, announced April 14, 2025 (EMA notice). The candidates still moving are below.
Beyond these, several other small molecule GLP-1 agonists are progressing through Phase 2 and Phase 3 trials across multiple companies. The interest is obvious: an effective oral GLP-1 removes the manufacturing bottlenecks that have plagued injectable supply chains, opens the category to patients who can't self-inject, and dramatically expands the addressable market.
The oral GLP-1 category two years from now will look very different from today. What's already here, though, is enough to shift prescribing decisions in a meaningful way — particularly orforglipron's no-fasting formulation, which removes one of the most common objections to oral semaglutide.
For people who want to explore injectable options that push efficacy further, the full landscape of Ozempic alternatives in 2026 covers where the category stands today. If you're specifically comparing the two oral semaglutide formulations, see the oral semaglutide pills guide. And for a direct breakdown of how oral compares to injectable on key clinical metrics, the oral vs. injectable semaglutide comparison goes deeper on the data.
FAQ
Sources
- Novo Nordisk. FDA approves Wegovy pill, the first oral GLP-1 for obesity (December 22, 2025)
- Wegovy (semaglutide) injection and tablets, US prescribing information (revised June 2026)
- Eli Lilly. FDA approves Foundayo (orforglipron) (April 1, 2026)
- Foundayo (orforglipron) tablets, US prescribing information (revised July 2026)
- Wharton S, et al. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment (ATTAIN-1). N Engl J Med. 2025;393:1796-1806. PMID 40960239
- Rybelsus and Ozempic (semaglutide) tablets, US prescribing information (revised January 2026)
- Novo Nordisk. FDA approves Wegovy HD injection (March 19, 2026)
- Wegovy savings and self-pay pricing (checked November 5, 2026)
- LillyDirect Foundayo self-pay pricing (checked November 5, 2026)
- NovoCare Ozempic pill and pen price guide
- CMS. Medicare GLP-1 Bridge
- Structure Therapeutics. Topline ACCESS data for aleniglipron (December 8, 2025), SEC exhibit 99.1
- Novo Nordisk. Zenagamtide phase 2 results at ADA 2026 (June 5, 2026)
- European Medicines Agency. Danuglipron: notification of discontinuation of paediatric development




